None listed
Conditions
Interventions
Drug : Receptor status is assessed by immunohistochemistry using recurrent tissues obtained from biopsy as determined by central laboratory. Dominant receptor, which means the receptor that has the hi
Sponsors
Inha University Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: - =19 age - Patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer (EOC): including all histologic types -Confirmation of recurrence using biopsy from primary or metastatic tissue -Palliative treatment setting: [(previous progression free or treatment free interval < 6months and 2 prior chemotherapy regimens) or (=3 prior chemotherapy regimens)] -ECOG Performance status 0-2 -Measurable lesion - Estimated life time =6months - Adequate hematologic and end organ function - During clinical trial, women of reproductive age should undergo adequate contraception, and should not perform breast feeding. Moreover, women should have negative pregnancy test performed immediately before clinical trial
Exclusion criteria
Exclusion criteria: -Patients who were diagnosed with other type of primary cancer within 5 years from diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube cancer (EOC): except cervical intraepithelial neoplasm -Cases that investigator decides as inadequate for study -Patient who has not been recovered from recent surgery -Patient having toxicity more than grade 2 of CTCAE originated from previous chemotherapy -Patient receiving immunotherapy or targeted therapy as anticancer therapy -History of venous thromboembolism -Pregnant women or women having possibility of pregnancy -Hypersensitivity for tamoxifen -Patient receiving combined therapy with Anstrozole -Patient having genetic disorders such as galactose intolerance, lapp lactase deficiency or glucose-galactose malaborption -Hypersensitivity for megestrol acetate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| discordance in hormonal receptor expression between tissues obtained from biopsies at enrollment and at time of disease progression;methylation status of hormonal receptors;Adverse events | — |
Countries
Korea, Republic of
Contacts
Public ContactEUNSUN LEE
KGOG(Korea Gynecologic Oncology Group)
Outcome results
None listed